ANIX

2.93

3.93% -0.12

Handel nachbörslich: 3.33 0.40 +13.65%

Anixa Biosciences Inc (ANIX)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$3.05

Offen:

$3.03

24-Stunden-Volumen:

188.08K

Relative Volume:

1.11

Marktkapitalisierung:

$99.69M

Einnahmen:

$210.00K

Nettoeinkommen (Verlust:

$-10.40M

KGV:

-9.3045

EPS:

-0.3149

Netto-Cashflow:

$-6.88M

1W Leistung:

+4.64%

1M Leistung:

+18.15%

6M Leistung:

-10.67%

1J Leistung:

-8.72%

1-Tages-Spanne:

$2.87

$3.08

1-Wochen-Bereich:

$2.74

$3.4842

52-Wochen-Spanne:

$2.32

$5.4566

Anixa Biosciences Inc Stock (ANIX) Company Profile

Firmenname

Anixa Biosciences Inc

Sektor

Healthcare (1094)

Branche

Biotechnology (615)

Telefon

408-708-9808

Adresse

3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE

Mitarbeiter

Twitter

@anixabio

Nächster Verdiensttermin

2026-06-10

Neueste SEC-Einreichungen

ANIX's Discussions on Twitter

Compare ANIX vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ANIX Anixa Biosciences Inc	2.93	103.77M	210.00K	-10.40M	-6.88M	-0.3149
VRTX Vertex Pharmaceuticals Inc	522.25	134.41B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	676.23	68.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	919.93	57.01B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	321.50	41.79B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	190.46	40.39B	742.00K	-1.37B	-1.07B	-7.0731

Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-03-21	Eingeleitet	Maxim Group	Buy
2022-12-23	Eingeleitet	Chardan Capital Markets	Buy
2021-04-12	Eingeleitet	H.C. Wainwright	Buy

Anixa Biosciences Inc Aktie (ANIX) Neueste Nachrichten

08:30 AM

Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Trial to Highest Dose Cohort - HLTH

08:30 AM

01:47 AM

Anixa Biosciences Treats First Patient in Fifth Cohort of Ovarian Cancer CAR-T Clinical Trial - Moomoo

01:47 AM

Jul 06, 2026

Anixa doses first patient in highest cohort of ovarian trial - Investing.com

Jul 06, 2026

Anixa Biosciences announced that in its clinical trial of CAR-T cell therapy, no dose-limiting toxicities were observed up to the previously established 3x10⁶/kg dose level. - Bitget

Jul 06, 2026

Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date - PR Newswire

Jul 06, 2026

Jul 04, 2026

Anixa Biosciences secures Korean patent for breast cancer vaccine - Yahoo Finance

Jun 30, 2026

Anixa Biosciences Granted First Korean Patent for its Breast Can - GuruFocus

Jun 30, 2026

Jun 29, 2026

Anixa receives South Korean patent for breast cancer vaccine - Investing.com

Jun 29, 2026

Anixa Biosciences (ANIX) Secures Patent for Breast Cancer Vaccine Technology - GuruFocus

Jun 29, 2026

Anixa receives South Korean patent for breast cancer vaccine By Investing.com - Investing.com South Africa

Jun 29, 2026

Anixa Secures Patent for Breast Cancer Vaccine in South Korea - Intellectia AI

Jun 29, 2026

Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040 - PR Newswire

Jun 29, 2026

Jun 27, 2026

Anixa Biosciences, Inc. Actuals & Estimates (NASDAQ:ANIX) - TradingView

Jun 27, 2026

Jun 26, 2026

Anixa Biosciences, Inc. Actuals & Estimates (DUS:CY71) - TradingView

Jun 26, 2026

Price to sales forward of Anixa Biosciences, Inc. – NASDAQ:ANIX - TradingView

Jun 26, 2026

Anixa presents breast cancer vaccine, ovarian CAR-T trial data - Investing.com UK

Jun 26, 2026

Anixa Biosciences (ANIX) Showcases Immunotherapy Progress at Key Symposium - GuruFocus

Jun 26, 2026

Anixa presents breast cancer vaccine, ovarian CAR-T trial data By Investing.com - Investing.com Australia

Jun 26, 2026

Enterprise value to revenue forward of Anixa Biosciences, Inc. – NASDAQ:ANIX - TradingView

Jun 26, 2026

Anixa Biosciences stock falls despite Phase 1 trial updates By Investing.com - Investing.com Nigeria

Jun 26, 2026

Anixa Biosciences stock falls despite Phase 1 trial updates - Investing.com

Jun 26, 2026

Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium - Barchart.com

Jun 26, 2026

Enterprise value to EBIT forward of Anixa Biosciences, Inc. – NASDAQ:ANIX - TradingView

Jun 26, 2026

Price to earnings forward of Anixa Biosciences, Inc. – NASDAQ:ANIX - TradingView

Jun 26, 2026

ANIX Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026

Jun 25, 2026

Anixa Biosciences, Inc. Actuals & Estimates (SWB:CY71) - TradingView

Jun 25, 2026

Here's Why You Should Add ANIX Stock to Your Portfolio Now - The Globe and Mail

Jun 25, 2026